Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions.
With the introduction of three new anti-epileptic drugs (AEDs) in the UK during the past 4 years as adjunctive add-on therapy, the possibility of AED pharmacokinetic interactions has become a relevant consideration. This review highlights the current status of AED interactions with particular emphasis on those interactions that are likely to be frequently experienced or whose outcome is potentially clinically significant.
Patsalos
P N
PN
Pharmacology and Therapeutics Unit, Chalfont Centre for Epilepsy, Bucks, UK.
D000085:Acetates / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004347:Drug Interactions; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D000077206:Gabapentin; D006801:Humans; D008657:Metabolic Clearance Rate / Q000502:physiology; D010634:Phenobarbital / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D010634:Phenobarbital